by Thomas A. Paul, Juraj Bies, Donald Small, and Linda Wolff

Slides:



Advertisements
Similar presentations
Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Germline Epigenetic Regulation of KILLIN in Cowden.
Advertisements

Volume 3, Issue 4, Pages (April 2013)
Volume 7, Issue 5, Pages (November 2016)
Volume 20, Issue 5, Pages (November 2011)
Volume 135, Issue 1, Pages e3 (July 2008)
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted.
Volume 8, Issue 5, Pages (May 2017)
The C/EBPδ tumor suppressor is silenced by hypermethylation in acute myeloid leukemia by Shuchi Agrawal, Wolf-Karsten Hofmann, Nicola Tidow, Mathias Ehrich,
P16 INK4a andp15 INK4b gene methylations in plasma cells from monoclonal gammopathy of undetermined significance by Gaëlle Guillerm, Emmanuel Gyan, Darius.
Lineage-inappropriate PAX5 expression in t(8;21) acute myeloid leukemia requires signaling-mediated abrogation of polycomb repression by Debleena Ray,
Epigenetic mechanisms silence a disintegrin and metalloprotease 33 expression in bronchial epithelial cells  Youwen Yang, PhD, Hans Michael Haitchi, MD,
Sensitivity of RNA‐seq.
Volume 3, Issue 4, Pages (April 2013)
WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukemia cell growth as a tumor suppressor by Jianming Ying, Hongyu Li, Yun-Wen.
Epigenetic Inhibition of Nuclear Receptor Small Heterodimer Partner Is Associated With and Regulates Hepatocellular Carcinoma Growth  Nan He, Kyungtae.
Developmental- and differentiation-specific patterns of human γ- and β-globin promoter DNA methylation by Rodwell Mabaera, Christine A. Richardson, Kristin.
Volume 47, Issue 2, Pages (July 2012)
Array-CGH Reveals Recurrent Genomic Changes in Merkel Cell Carcinoma Including Amplification of L-Myc  Kelly G. Paulson, Bianca D. Lemos, Bin Feng, Natalia.
Experimental Hematology
Volume 135, Issue 1, Pages e3 (July 2008)
The interferon regulatory factor ICSBP/IRF-8 in combination with PU
Volume 62, Issue 3, Pages (May 2016)
Volume 11, Issue 6, Pages (June 2007)
Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia by Floriana Manodoro, Jacek Marzec, Tracy.
Demethylation of a nonpromoter cytosine-phosphate-guanine island in the aromatase gene may cause the aberrant up-regulation in endometriotic tissues 
Volume 26, Issue 4, Pages (October 2014)
by Kentson Lam, Alexander Muselman, Randal Du, Yuka Harada, Amanda G
S. Sesselmann, M. D. , S. Söder, M. D. , R. Voigt, J. Haag, Ph. D. , S
The Hematopoietic Stem Cell Regulatory Gene Latexin Has Tumor-Suppressive Properties in Malignant Melanoma  Viswanathan Muthusamy, Sanjay Premi, Cara.
Volume 44, Issue 1, Pages (October 2011)
Volume 81, Issue 4, Pages (February 2014)
Volume 21, Issue 5, Pages e7 (November 2017)
Reversing the TERT promoter mutation to WT reverses the active chromatin marks and alters long-range chromatin interactions. Reversing the TERT promoter.
Volume 7, Issue 5, Pages (November 2016)
Volume 11, Issue 6, Pages (June 2007)
Epigenetic regulation of miR-193b in liposarcomagenesis.
Volume 2, Issue 2, Pages (February 2008)
Volume 23, Issue 1, Pages 9-22 (January 2013)
Volume 7, Issue 9, Pages (September 2014)
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia by Jianting Long, Brian.
Bo-Kuan Wu, Charles Brenner  Cell Reports 
Volume 11, Issue 2, Pages (April 2015)
MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs by Silvia Maifrede, Esteban Martinez, Margaret Nieborowska-Skorska, Daniela.
Volume 10, Issue 3, Pages (March 2018)
Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma  Soonyean Hwang, Hye-Eun Kim, Michelle Min, Rekha.
Germline Epigenetic Silencing of the Tumor Suppressor Gene PTPRJ in Early-Onset Familial Colorectal Cancer  Ramprasath Venkatachalam  Gastroenterology 
Volume 12, Issue 5, Pages (November 2007)
Volume 72, Issue 2, Pages e5 (October 2018)
Imprinted Chromatin around DIRAS3 Regulates Alternative Splicing of GNG12-AS1, a Long Noncoding RNA  Malwina Niemczyk, Yoko Ito, Joanna Huddleston, Anna.
Laura Lande-Diner, Jianmin Zhang, Howard Cedar  Molecular Cell 
Olivier Humbert, Nancy Maizels  Molecular Therapy - Nucleic Acids 
Volume 15, Issue 1, Pages (April 2016)
Core promoter methylation in mediators of adipogenesis.
Volume 10, Issue 1, Pages (January 2018)
Volume 20, Issue 4, Pages (April 2011)
Epigenetic Control of the S100A6 (Calcyclin) Gene Expression
The human GPR109A promoter is methylated and GPR109A expression is silenced in human colon carcinoma cells. The human GPR109A promoter is methylated and.
Differential binding of H3K36me3 in G34-mutant KNS42 cells drives pediatric GBM expression signatures. Differential binding of H3K36me3 in G34-mutant KNS42.
Multiple Epigenetic Modifiers Induce Aggressive Viral Extinction in Extraembryonic Endoderm Stem Cells  Michael C. Golding, Liyue Zhang, Mellissa R.W.
Volume 1, Issue 3, Pages (September 2007)
Decreased expression of cell cycle– and apoptosis-related genes in Aml1-excised leukemia cell. Decreased expression of cell cycle– and apoptosis-related.
Volume 28, Issue 4, Pages (February 2014)
Influence of RdDM on DCL4 Transcript Isoform Expression.
Epigenetic regulation of p16INK4a in human gastric cancer.
DNA hypermethylation silences TRAIL in transformed cells.
A, high-resolution methylation analysis of ZNF545 promoter by BGS in representative carcinoma cell lines. A, high-resolution methylation analysis of ZNF545.
The ITGAL promoter is methylated in fibroblasts but not T cells
Specific DNA methylation and expression signatures associated with binding of E2A–PBX1 fusion protein. Specific DNA methylation and expression signatures.
Bradford Coffee, Fuping Zhang, Stephanie Ceman, Stephen T
Mutant TERT promoter displays active histone marks and distinct long-range interactions: A, cell lines that were used in the study with their origin and.
Presentation transcript:

by Thomas A. Paul, Juraj Bies, Donald Small, and Linda Wolff Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML by Thomas A. Paul, Juraj Bies, Donald Small, and Linda Wolff Blood Volume 115(15):3098-3108 April 15, 2010 ©2010 by American Society of Hematology

p15INK4b DNA methylation and expression in AML cell lines used in study. p15INK4b DNA methylation and expression in AML cell lines used in study. (A) Bisulfite sequencing of the p15INK4b exon 1 CpG island. Filled circles represent percentage of DNA methylation at CpG positions from 10 independently sequenced clones (● represents ≥ 50% methylcytosine; , 10%-49% methylcytosine). (B-C) Quantitative reverse-transcriptase (RT)–PCR analysis of p15INK4b, p14ARF, and p16INK4a expression in AML cell lines. Copies of cDNA per 100 ng of total RNA were calculated from a plasmid DNA standard curve and represent the averages of 3 independent experiments with error bars of SD. Thomas A. Paul et al. Blood 2010;115:3098-3108 ©2010 by American Society of Hematology

Distribution of H3K4me3, H3K27me3, and EZH2 at INK4b-ARF-INK4a differs in AML cell lines with DNA methylation. Distribution of H3K4me3, H3K27me3, and EZH2 at INK4b-ARF-INK4a differs in AML cell lines with DNA methylation. ChIP-on-chip analysis of enrichment of H3K4me3 (blue), H3K27me3 (red) on chromosome 9: 21800000 to 22450000 (A) and chromosome 9: 21953000 to 22003000 (B) in AML cell lines. Top axis represents H3K4me3; and bottom axis, H3K27me3. Enrichment of EZH2 (green; C) and H3K9me3 (orange; D) at the INK4b-ARF-INK4a region in AML cell lines. Normalized enrichment data (IP/input) are plotted on a log 2 scale. Thomas A. Paul et al. Blood 2010;115:3098-3108 ©2010 by American Society of Hematology

AML patient blasts with p15INK4b DNA methylation display reduced H3K4me3 enrichment at the promoter. AML patient blasts with p15INK4b DNA methylation display reduced H3K4me3 enrichment at the promoter. (A) Bisulfite sequencing of the p15INK4b exon 1 CpG island in AML patient samples. Filled circles represent the frequency of DNA methylation at CpG positions in sequenced clones (● represents ≥ 50% methylcytosine; , 10%-49% methylcytosine). (B) Quantitative RT-PCR analysis of p15INK4b expression in AML patient blasts. cDNA copies per 50 ng total RNA were calculated from a plasmid DNA standard curve and represent the averages of 3 independent experiments with error bars of SD. Quantitative PCR analysis (C) of H3K4me3 and H3K27me3 enrichment at the p15INK4b promoter. Data are averages of ΔΔCt compared with input DNA from 3 technical replicates with error bars of SD. ChIP-on-chip analysis of enrichment of H3K4me3 (blue) and H3K27me3 (red) on chromosome 9: 21953000 to 22003000 (D) and chromosome 9: 21990000 to 22003000 (E) in AML patient samples. Top axis represents H3K4me3; and bottom axis, H3K27me3. Normalized enrichment data (IP/input) are plotted on a log 2 scale. Thomas A. Paul et al. Blood 2010;115:3098-3108 ©2010 by American Society of Hematology

Reactivation of p15INK4b expression and loss of DNA methylation after treatment with DNMT or HDAC inhibitors. Reactivation of p15INK4b expression and loss of DNA methylation after treatment with DNMT or HDAC inhibitors. (A) Quantitative RT-PCR analysis of p15INK4b expression in KG-1, KG-1a, and AML-193 cells after reactivation with 5-aza-dC and/or TSA. (B) Quantitative RT-PCR for p15INK4b, p14ARF, and p16INK4a expression in KG-1cells after reactivation with 5-aza-dC and/or TSA. (A-B) *Increase in expression relative to control (P < .05, 1-way analysis of variance). (C) Quantitative RT-PCR for p15INK4b expression in AML patient blasts treated with 5-aza-dC or TSA. Quantitative RT-PCR data in both cell lines and clinical samples were normalized to control cells and calculated from ΔΔCt averages of 3 independent experiments with error bars of SD. *Significant increase in expression in cells treated with a combination of 5-aza-dC and TSA compared with cells treated with 5-aza-dC alone (P < .05, 1-way analysis of variance). (D) Bisulfite sequencing of the p15INK4b CpG island in individual clones from control and treated KG-1, AML-193, and AML8 blasts after treatment with 5-aza-dC and/or TSA. Filled circles represent percentage DNA methylation at individual CpG positions from 10 independently sequenced clones (● represents ≥ 50% methylcytosine; , 10%-49% methylcytosine). Thomas A. Paul et al. Blood 2010;115:3098-3108 ©2010 by American Society of Hematology

Reactivation of p15INK4b using DNMT and HDAC inhibitors is associated with an increase in H3K4me3 and maintenance of H3K27me3 in KG-1 and AML blasts. Reactivation of p15INK4b using DNMT and HDAC inhibitors is associated with an increase in H3K4me3 and maintenance of H3K27me3 in KG-1 and AML blasts. ChIP-quantitative PCR measured enrichment of H3K4me3 and H3K27me3 at the p15INK4b promoter after reactivation in KG-1 (A) and AML-193 cells (B). The enrichment of H3K4me3 (C) and H3K27me3 (D) measured at the p15INK4b promoter by quantitative PCR in clinical samples AML8, AML9, AML10, and AML11 patient blasts treated with DMSO (control), 5-aza-dC, or TSA. (C) *Significant increase in H3K4me3 enrichment compared with control treatment (P < .05, 1-way analysis of variance). Enrichment was calculated from ΔΔCt averages of 3 independent experiments with error bars of SD. (E) ChIP-on-chip for enrichment of H3K4me3 (blue) and H3K27me3 (red) at INK4b-ARF-INK4a in DMSO control and 5-aza-dC plus TSA-treated KG-1 and AML-193 cells. (F) ChIP-on-chip for enrichment of H3K4me3 (blue) and H3K27me3 (red) at INK4b-ARF-INK4a in AML8 patient blasts treated with control DMSO, 5-aza-dC, or TSA. Normalized enrichment data (IP/input) are plotted on a log 2 scale. Thomas A. Paul et al. Blood 2010;115:3098-3108 ©2010 by American Society of Hematology